Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954421 | 0.86 | DPP8 (0.39) | KCNQ2LMNASMN1; SMN2ALDH1A1S1PR3 | |
| SCHEMBL895915 | 0.82 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL895816 | 0.81 | AKR1C3 (0.41) | LMNASMN1; SMN2ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL3746240 | 0.78 | CXCL8 (0.42) | LMNASMN1; SMN2ALDH1A1S1PR3AKR1C3 | |
| SCHEMBL896359 | 0.78 | AKR1C3 (0.38) | KCNQ2LMNASMN1; SMN2ALDH1A1AKR1C3 | |
| SCHEMBL896615 | 0.77 | AKR1C3 (0.46) | AKR1C3AKR1C2DHODH | |
| SCHEMBL28193413 | 0.77 | NPC1 (0.40) | LMNASMN1; SMN2ALDH1A1S1PR3NPC1 | |
| SCHEMBL1331826 | 0.76 | CYP2D6 (0.36) | S1PR3NPC1RAB9AS1PR1KMT2A | |
| SCHEMBL31561709 | 0.76 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1S1PR3NPC1 | |
| SCHEMBL1268313 | 0.76 | ALDH1A1 (0.57) | LMNASMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | KCNQ2 1137/4885LMNA 2869/4885SMN1; SMN2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.